Literature DB >> 16371632

Oseltamivir resistance during treatment of influenza A (H5N1) infection.

Menno D de Jong1, Tan Thanh Tran, Huu Khanh Truong, Minh Hien Vo, Gavin J D Smith, Vinh Chau Nguyen, Van Cam Bach, Tu Qui Phan, Quang Ha Do, Yi Guan, J S Malik Peiris, Tinh Hien Tran, Jeremy Farrar.   

Abstract

Influenza A (H5N1) virus with an amino acid substitution in neuraminidase conferring high-level resistance to oseltamivir was isolated from two of eight Vietnamese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient. Surviving patients had rapid declines in the viral load to undetectable levels during treatment. These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents. Copyright 2005 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371632     DOI: 10.1056/NEJMoa054512

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  326 in total

Review 1.  Methods for molecular surveillance of influenza.

Authors:  Ruixue Wang; Jeffery K Taubenberger
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 2.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

3.  Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Authors:  Naveen Kumar; Nishi R Sharma; Hinh Ly; Tristram G Parslow; Yuying Liang
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

4.  Mast cell-induced lung injury in mice infected with H5N1 influenza virus.

Authors:  Yanxin Hu; Yi Jin; Deping Han; Guozhong Zhang; Shanping Cao; Jingjing Xie; Jia Xue; Yi Li; Di Meng; Xiaoxu Fan; Lun-Quan Sun; Ming Wang
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

5.  Q&A: Reasons for proposed redaction of flu paper.

Authors:  Paul S Keim
Journal:  Nature       Date:  2012-01-31       Impact factor: 49.962

Review 6.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

7.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 8.  The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.

Authors:  Carlos del Rio; Jeannette Guarner
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

Review 9.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

10.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.